Expanding Portfolio AffaMed Therapeutics is actively developing and commercializing innovative ophthalmic, neurological, and psychiatric products, including novel intraocular lenses and digital therapies, presenting diversified sales opportunities across multiple medical specialties.

Strategic Partnerships The company's collaborations with global biopharmaceutical firms like Allgenesis, VistaGen, Ocular Therapeutix, and Eli Lilly indicate strong industry recognition and open avenues for joint product launches, licensing, and regional expansion in Greater China and Southeast Asia.

Growing Market Presence With recent product launches such as EVOLUX and ongoing licensing agreements, AffaMed is positioning itself as a key player in the Chinese ophthalmic and neurological markets, creating opportunities to offer innovative solutions to hospitals and clinics.

Funding and Revenue Having secured significant funding of around $170 million and generating revenues between $50 million and $100 million, AffaMed demonstrates financial stability, enabling sales teams to target healthcare providers actively adopting new advanced therapies.

Technology Integration Utilizing advanced digital technologies and cloud infrastructure like Microsoft Azure and Kubernetes, AffaMed enhances its R&D capabilities and clinical trials, providing opportunities to collaborate on digital health innovations and related medical devices.